{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:12:07Z","timestamp":1772190727888,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.ejpb.2007.03.010","type":"journal-article","created":{"date-parts":[[2007,3,20]],"date-time":"2007-03-20T10:51:22Z","timestamp":1174387882000},"page":"361-369","source":"Crossref","is-referenced-by-count":92,"title":["Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: Can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis\/therapy?"],"prefix":"10.1016","volume":"67","author":[{"given":"D.D.","family":"Ankola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Viswanad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ramarao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.N.V. Ravi","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2007.03.010_bib1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2006.04.015","article-title":"Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective","volume":"113","author":"Ratnam","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2007.03.010_bib2","series-title":"Biomedical and Clinical Aspects of Coenzyme Q","first-page":"375","article-title":"Biomedical and clinical research on coenzyme Q10 with emphasis on cardiac patients","author":"Folkers","year":"1986"},{"key":"10.1016\/j.ejpb.2007.03.010_bib3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0003-9861(92)90511-T","article-title":"Distribution and redox state of ubiquinone in rat and human tissues","volume":"295","author":"Aberg","year":"1992","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejpb.2007.03.010_bib4","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/0098-2997(94)90026-4","article-title":"Usefulness of coenzyme Q10 in clinical cardiology: a long term study","volume":"15","author":"Langsjoen","year":"1994","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.ejpb.2007.03.010_bib5","article-title":"Coenzyme Q10 and cardiovascular health: to take or not to take \u2013 that is the question","volume":"10","author":"Joo","year":"2005","journal-title":"Nutr. Bytes"},{"key":"10.1016\/j.ejpb.2007.03.010_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1006\/bbrc.1997.6522","article-title":"Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer","volume":"234","author":"Folkers","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejpb.2007.03.010_bib7","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease \u2013 evidence of slowing down of the functional decline","volume":"59","author":"Shults","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejpb.2007.03.010_bib8","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1073\/pnas.87.22.8931","article-title":"critique of 25 years of research which culminated in the successful therapy of periodontal disease with coenzyme Q levels in humans","volume":"87","author":"Folkers","year":"1992","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2007.03.010_bib9","first-page":"262","article-title":"Relative bioavailability of coenzyme Q10 formulations","volume":"38","author":"Chopra","year":"1998","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.ejpb.2007.03.010_bib10","first-page":"109","article-title":"Relative bioavailability of coenzyme Q10 formulations in human subjects","volume":"68","author":"Chopra","year":"1998","journal-title":"Int. J. Vitam. Nutr. Res."},{"key":"10.1016\/j.ejpb.2007.03.010_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1166\/jbn.2005.033","article-title":"Pharmaceutical aspects of polymeric nanoparticles for oral delivery","volume":"1","author":"Bhardwaj","year":"2005","journal-title":"J. Biomed. Nanotech."},{"key":"10.1016\/j.ejpb.2007.03.010_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i5.20","article-title":"PLGA nanoparticles in drug delivery: the state of the art","volume":"21","author":"Bala","year":"2004","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ejpb.2007.03.010_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0169-409X(98)00047-7","article-title":"Oral particulate delivery: status and future trends","volume":"34","author":"Chen","year":"1998","journal-title":"Adv. Drug Del. Rev."},{"key":"10.1016\/j.ejpb.2007.03.010_bib14","doi-asserted-by":"crossref","DOI":"10.1208\/ps030108","article-title":"pH-dependent dissolving nano- and microparticles for improved peroral delivery of a highly lipophilic compound in dogs","volume":"3","author":"Jaeghere","year":"2001","journal-title":"AAPS Pharmsci."},{"key":"10.1016\/j.ejpb.2007.03.010_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0168-3659(02)00320-6","article-title":"A novel controlled release formulation for the anticancer drug paclitaxel (Taxol(R)): PLGA nanoparticles containing vitamin E TPGS","volume":"86","author":"Mu","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2007.03.010_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0169-409X(98)00041-6","article-title":"Evaluation of nano- and microparticle uptake by the gastrointestinal tract","volume":"34","author":"Delie","year":"1998","journal-title":"Adv. Drug Del. Rev."},{"key":"10.1016\/j.ejpb.2007.03.010_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0169-409X(01)00152-1","article-title":"Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics","volume":"50","author":"Hussain","year":"2001","journal-title":"Adv. Drug Del. Rel."},{"key":"10.1016\/j.ejpb.2007.03.010_bib18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11095-005-8418-y","article-title":"Design of estradiol loaded PLGA nanopaticles formulations: a potential oral delivery system for hormone therapy","volume":"23","author":"Hariharan","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2007.03.010_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.2042-7158.1972.tb08877.x","article-title":"A modified silver clip used in the induction of renal hypertension in the rat","volume":"24","author":"Burns","year":"1972","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2007.03.010_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1152\/jappl.1971.31.1.142","article-title":"A solid silver clip for induction of predictable levels of renal hypertension in the rat","volume":"31","author":"Leenen","year":"1971","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.ejpb.2007.03.010_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.cardiores.2004.10.010","article-title":"AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats","volume":"65","author":"Arun","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejpb.2007.03.010_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","article-title":"Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction","volume":"95","author":"Ohkawa","year":"1979","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejpb.2007.03.010_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10611860600565987","article-title":"Sustained release nanoparticulate formulation containing antioxidant ellagic acid as potential prophylaxis system for oral administration","volume":"14","author":"Bala","year":"2006","journal-title":"J. Drug. Target."},{"key":"10.1016\/j.ejpb.2007.03.010_bib24","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1088\/0957-4484\/16\/12\/014","article-title":"Design of biodegradable nanoparticles: a novel approach to encapsulating poorly soluble phytochemical ellagic acid","volume":"16","author":"Bala","year":"2005","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ejpb.2007.03.010_bib25","first-page":"56","article-title":"Acceptable analytical practices for dissolution testing of poorly soluble compounds","author":"Brown","year":"2004","journal-title":"Pharm. Tech."},{"key":"10.1016\/j.ejpb.2007.03.010_bib26","first-page":"149","article-title":"Effect of coenzyme Q10 on experimental hypertension in rats and dogs","volume":"189","author":"Igarashi","year":"1974","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2007.03.010_bib27","first-page":"487","article-title":"Reduction by coenzyme Q10 of hypertension induced by deoxycorticosterone and saline in rats","volume":"44","author":"Yamagami","year":"1974","journal-title":"Int. J. Vitam. Nutr. Res."},{"key":"10.1016\/j.ejpb.2007.03.010_bib28","doi-asserted-by":"crossref","first-page":"s265","DOI":"10.1016\/0098-2997(94)90037-X","article-title":"Treatment of essential hypertension with coenzyme Q10","volume":"15","author":"Langsjoen","year":"1994","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.ejpb.2007.03.010_bib29","doi-asserted-by":"crossref","first-page":"s257","DOI":"10.1016\/0098-2997(94)90036-1","article-title":"Coenzyme Q10 in essential hypertension","volume":"15","author":"Digiesi","year":"1994","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.ejpb.2007.03.010_bib30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1054\/mehy.1997.0761","article-title":"Coenzyme Q versus hypertension: does CoQ decreases endothelial superoxide generation?","volume":"53","author":"Mccarthy","year":"1999","journal-title":"Med. Hypotheses"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641107000987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641107000987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T13:58:15Z","timestamp":1556287095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641107000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0939641107000987"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2007.03.010","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}